Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Date:6/1/2009

CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung were presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting is being held in Orlando, Florida from May 29 to June 2, 2009.

The presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" was delivered by Dr. Monica Mita, the study principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The interim results demonstrate that the treatment has been well tolerated, with 15 of 36, or 42% of evaluable patients experiencing stable disease (SD) for more than 16 weeks, including five patients who have had SD for more than 24 weeks. One patient had SD for more than 80 weeks. Oncolytics reported on May 12, 2009, that full enrolment of 52 patients was completed, at which time nine patients were continuing on study.

"The ASCO data are very encouraging, both in terms of efficacy in patients with sarcoma, and in those with other tumor histologies in whom the IDD group are investigating various REOLYSIN regimens," said Dr. Frank Giles, Director, IDD, and Deputy Director, CTRC at UTHSCSA.

Additional REOLYSIN results presented

Two additional poster presentations covering positive results of REOLYSIN trials were also presented at the ASCO meeting on May 30, 2009.

Dr. Johann de Bono and colleagues delivered a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemci
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
2. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
3. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
4. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
6. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
7. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
8. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
10. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Wash. , July 31, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... second quarter 2014 financial results will be released on ... host a conference call and live webcast at 4:30 ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SNY) today announced that the Companies intend to use ... disease priority review voucher in connection with the Biologics ... voucher entitles the holder to designate a BLA for ... from the filing date instead of the standard 10-month ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... Baltimore Convention Center - September 21-23, 2009 ... summit will attract more than 1,200 experts from more than 25 ... 100 speakers, including governors, federal officials, and top researchers and scientists ... human-interest stories. This is your chance to meet and talk ...
... Aug. 11 ValGenesis, Inc., a leading provider ... availability of Microsoft SharePoint Server integration with the ... productivity specifically for regulated Pharmaceuticals, Biotech and Medical ... access, retrieval and storage of corporate validation data ...
... , NEWTON, Mass., Aug. 11 Microfluidics International Corporation ... quarter ended June 30, 2009. , , ... quarter accomplishments: , , Achieved positive ... Delivered strong bookings of $6.6 million with ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 9
(Date:7/31/2014)... July 31, 2014 Biometrics industry ... innovative smart technologies; companies turn towards digital currency: NXT-ID, ... ), Amazon.com Inc. (NASDAQ: AMZN ), Facebook ... GOOG ) and Microsoft Corporation (NASDAQ: MSFT) ... on the growing m-commerce market, announces a video featuring ...
(Date:7/30/2014)... York University is paving the way for a ... and military troops exposed to poisonous chemicalsparticularly those ... article in the current issue of the journal ... organophosphates, which are compounds commonly used in pesticides ... by NYU School of Engineering Associate Professor of ...
(Date:7/30/2014)... Chemical Society (ACS) announced today that David L. Kaplan, ... Biomaterials Science & Engineering as editor-in-chief. With the ... new journal will feature high-quality research in the rapidly ... naturally derived materials that interact with living or biological ... reflects the tremendous growth in the field of biomaterials ...
Breaking Biology News(10 mins):Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... is threatening the time-honored transmission of plant knowledge from ... and nutrition. In a novel study published online this ... Sciences, researchers report that parents, and especially mothers, who ... have healthier children, independent of other factors such as ...
... National Museum of Natural History in Washington, D.C., have ... of what they regard as one of the weirdest ... that the organism was a fungus, the scientists report ... published by the Geological Society of America. Called Prototaxites ...
... long been known that UV light can damage DNA, reducing ... resulting in the development of skin cancers. However, not much ... altered upon exposure to UV light. Now a group of ... changes in the mechanical properties of DNA upon irradiation with ...
Cached Biology News:Mother knows best: Plant knowledge key to childhood health in remote Amazon 2Prehistoric mystery organism verified as giant fungus 2Prehistoric mystery organism verified as giant fungus 3Prehistoric mystery organism verified as giant fungus 4Stretching DNA to the limit 2